Inflammatory mediators and reversible myocardial dysfunction

Journal of Cellular Physiology

Volumn 195, Issue 1, 2003, Pages 1-11

  Kan, Hong ^a   Finkel, Mitchell S ^a,b,c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b Louis A Johnson VA Medical Center   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE;

ADRENERGIC STIMULATION; APOPTOSIS; CARDIOMYOPATHY; CELL PROLIFERATION; CYTOKINE PRODUCTION; DESENSITIZATION; DISEASE COURSE; ELECTRON TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART DEPOLARIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION PREVENTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEMODYNAMIC MONITORING; HUMAN; INOTROPISM; MYOCARDIAL DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSPORT KINETICS;

ANIMALS; CARDIOMYOPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION MEDIATORS; MYOCARDIAL CONTRACTION; MYOCARDIUM; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0037375028     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10213     Document Type: Review

References (115)

1. Abe J, Baines CP, Berk BC. 2000. Role of mitogen-activated protein kinases in ischemia and reperfusion injury. The good and the bad. Circ Res 86:607-609.
2. Akaike T, Maeda H. 2000. Nitric oxide and virus infection. Immunology 101(3):300-308.
3. Anderson DW, Virmani R, Reilly JM, O'Leary T, Cunnion RE, Robinowitz M, Macher AM, Punja U, Villaflor ST, Parrillo JE, et al. 1988. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol 11(4):792-799.
4. Ashley EA, Sears CE, Byrant SM, Watkins HC, Casadei B. 2002. Cardiac nitric oxide synthase 1 regulates basal and-adrenergic contractility in murine ventricular myocytes. Circulation 105:3011-3016.
5. Badorff C, Berkely N, Mehrotra S, Talhouk JW, Rhoads RE, Knowlton KU. 2000a. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J Biol Chem 275(15):11191-11197.
6. Badorff C, Fichtlscherer B, Rhoads RE, Zeiher AM, Muelsch A, Dimmeler S, Knowlton KU. 2000b. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Circulation 102(18):2276-2281.
7. Baines CP, Wang L, Cohen MV, Downey JM. 1998. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol 30:383-392.
8. Ballard-Croft C, White DJ, Maass DL, Hybki DP, Horton JW. 2001. Role of p38 MAP kinase in cardiac myocyte secretion of the inflammatory cytokine TNF-alpha. Am J Physiol 280(5):H1970-H1981.
9. Balligand JL, Kobzik L, Han X, Kaye DM, Belhassen L, O'Hara DS, Kelly RA, Smith TW, Michel T. 1995. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (Type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270(4):14582-14586.
10. Barbaro G. 2002. Cardiovascular manifestations of HIV infection. Circulation 106:1420-1425.
11. Barbaro G, Lorenzo GD, Grisorio B, Barbarini G. 1998. Incidence of dilated cardiomyopathy and detection of HIV in myocardial of HIV-positive patients. N Eng J Med 339:1093-1099.
12. Bers DM. 2002. Cardiac excitation-contraction coupling. Nature 415: 198-205.
13. Brady AJB, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE. 1993. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 265:H176-H182.
14. Braunwald E, Kloner RA. 1982. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 66:1146-1149.
15. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. 1991. Cloned and expressed mitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351:714-718.
16. Brown JM, Grosso MA, Terada LS. 1989. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 86:2516-2520.
17. Carroll R, Yellon DM. 2000. Delayed cardioprotection in a human cardiomyocyte-derived cell line: The role of adenosine, p38MAP kinase, and mitochondrial KATP. Basic Res Cardiol 95:243-249.
18. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Eng J Med 311:819.
19. Communal C, Singh K, Pimentel DR, Colucci WS. 1998. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98(13): 1329-1334.
20. i-dependent activation. J Biol Chem 275:19395-19400.
21. The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survial Study (CONSENSUS). N Engl J Med 316:1429-1435.
22. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. 1996. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: Implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci USA 93:1619-1623.
23. Coplan JD, Trost RC, Owens MJ, Cooper TB, Gorman JM, Nemeroff CB, Rosenblum LA. 1998. Cerebrospinal fluid concentrations of somatostatin and biogenic amines in grown primates reared by mothers exposed to manipulated foraging conditions. Arch Gen Psychiatry 55:473-477.
24. Corasaniti MT, Strongoli MC, Piccinilli S, Nistico R, Costa A, Bilotta A, Turano P, Finazzi-Agro A, Bagetta G. 2000. Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem Biophys Res Comm 274:664-669.
25. Deten A, Volz HC, Briest W, Zimmer HG. 2002. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 55(2):329-340.
26. Feldman MC, Gwarthmey JC, Phillips P, Schoen F, Morgan JP. 1988. Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol 3:273-283.
27. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C. 2000. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35:537-544.
28. Finkel MS. 1996. Effects of pro-inflammatory cytokines on the contractility of mammalian heart. Heart Fail Rev 1(3):203-210.
29. Finkel MS. 2000. Nitric oxide and viral cardiomyopathy (editorial) Circulation 102(18):2162-2164.
30. Finkel MS, Oddis CV, Jacobs TD, Watkins SC, Hattler BG, Simmons RL. 1992. Inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387-389.
31. Finkel MS, Oddis CV, Romeo RC, Salama G. 1993a. Positive inotropic effect of acetylcysteine in the cardiomyopathic Syrian hamster. J Cardiovasc Pharmacol 21:29-34.
32. Finkel MS, Shen L, Oddis CV, Hoffman RA, Romeo RC, Simmons RL, Hattler BG. 1993b. IL-6 as a mediator of stunned myocardium. Am J Cardiol 71:1231-1232.
33. Finkel MS, Oddis CV, Mayer OH, Hattler BG, Simmons RL. 1995. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship. J Pharm Exp Ther 272(2):945-952.
34. Frering B, Philip I, Dehoux M, Rolland C, Langlois JM, Desmonts JM. 1994. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 108:636-641.
35. Furchgott RF, Zawadzki JV. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789):373-376.
36. Guillen I, Blanes M, Gomez-Lechon MJ, Castell JV. 1995. Cytokine signaling during myocardial infarction: Sequential appearance of IL-1β and IL-6. Am J Physiol 269(Regulatory Integrative Comp Physiol 38):R229-R235.
37. Gulick T, Chung MK, Peiper SJ, Lange LG, Schreiner GF. 1989. Interleukin-1 and tumor necrosis factor inhibit cardiac myocytes? β-adrenergic responsiveness. Proc Natl Acad Sci USA 86:6753-6757.
38. Habib FM, Spingall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. 1996. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347:1151-1155.
39. Hattler BG, Gorcsan JIII, Shah N, Oddis CV, Billiar TR, Simmons RL, Finkel MS. 1994. A potential role for nitric oxide (NO) in myocardial stunning. J Card Surg 9:425-429.
40. Hattler BG, Oddis CV, Zeevi A, Luss H, Shah N, Geller DA, Billiar TR, Simmons RL, Finkel MS. 1995. Regulation of constitutive nitric oxide synthase activity by the human heart. Am J Cardiol 76:957-959.
41. 2 in the human astrocytoma cell line 1321N1. J Biol Chem 273:606-612.
42. Herskowitz A, Choi S, Ansari AA, Wesselingh S. 1995a. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 146:419-428.
43. Herskowitz A, Willoughby SB, Vlahov D, Baughman KL, Ansari AA. 1995b. Dilated heart muscle disease associated with HIV infection. Eur Heart J 16(Suppl O):50-55.
44. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. 1975. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 56(4):978-985.
45. Ho KK, Anderson KM, Kannel WB, et al. 1993. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88:107-115.
46. Hogan CM, Hammer SM. 2001a. Host determinants in HIV infection and disease. Part I: Cellular and humoral immune responses. Ann Intern Med 134:761-776.
47. Hogan CM, Hammer SM. 2001b. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 134:978-996.
48. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. 1987. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265-9269.
49. Ikeda U, Ohkawa F, Seino Y, Yamamotor K, Hidaka Y, Kasahara T, Kawai T, Shimada K. 1992. Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 24:579-584.
50. Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K. 1995. Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation 92:2683-2688.
51. Janeway CH, Travers P, Hunt S, Walport M. 2001a. Immunobiology: The immune system in health and disease. New York: Current Biology Limited; 2:64-88.
52. Janeway CH, Travers P, Hunt S, Walport M. 2001b. Immunobiology: The immune system in health and disease. New York: Current Biology Limited; 8:322-328.
53. Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Bloch KD. 1992. Cloning and expression of cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem 267:14519-14522.
54. Kan H, Finkel MS. 2001. Interactions between cytokines and neurohormonal systems in the failing heart. Heart Fail Rev 6: 119-127.
55. Kan H, Xie Z, Finkel MS. 1999a. Norepinephrine stimulated MAP kinase activity enhances cytokine induced nitric oxide production by neonatal rat cardiac myocytes. Am J Physiol 276:H47-H52.
56. Kan H, Xie Z, Finkel MS. 1999b. TNF enhances NO production by neonatal rat cardiac myocytes through MAP kinase mediated activation of NF-κB. Am J Physiol 277:H1641-H1646.
57. Kan H, Xie Z, Finkel MS. 2000. HIV gp120 enhances nitric oxide production by cardiac myocytes through p38 MAP kinase mediated NFκB activation. Am J Physiol 279:H3138-H3143.
58. Kan H, Birkle D, Xie S, Failinger C, Jain AC, Finkel MS. 2002a. P38 MAP kinase mediates myocardial dysfunction in prenatally stressed rats. JACC Abstract (in press).
59. Kan H, Xie Z, Finkel MS. 2002b. P38 MAP kinase regulates negative inotropic effect of HIV gp120 on cardiac myocytes through troponin I phosphorylation. FASEB J 16(4):A570.
60. Kanai AJ, Mesaros S, Finkel MS, Oddis CV, Strauss HC, Malinski T. 1997. Nitric oxide release measured directly with a porphyrinic microsensor reveals adrenergic control of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol 273(42):C1371-C1377.
61. Katz AM. 2001. Physiology of the heart, 2nd edition. New York: Raven Press.
62. Kaul M, Lipton SA. 1999. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 96(14):8212-8216.
63. Kelly RA, Balligand JL, Smith TW. 1996. Nitric oxide and cardiac function. Circ Res 79:363-380.
64. Kloner RA, Shook T, Przyklenk K, Davis VG, et al. 1995. Previous angina alters in-hospital outcome in TIMI-4. A clinical correlate to preconditioning? Circulation 91:37-47.
65. Kubota T, Miyagishima M, Alvarez RJ, Kormos R, Rosenblum WD, Demetris AJ, Semigran MJ, Dec GW, Holubkov R, McTiernan CF, Mann DL, Feldman AM, McNamara DM. 2000. Expression of proinflammatory cytokines in the failing human heart: Comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant 19(9):819-824.
66. Kumar AR, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. 1999. Role of nitric oxide and cAMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 276:R265-R276.
67. Levine B, Kalman J, Mayer L, Filit HM, Packer M. 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 323(4):236-241.
68. 2 HIV multicenter study. Circulation 102:1542-1548.
69. 2+ current by interleukin-1 beta in cultured rat ventricular myocytes. Am J Physiol 268(2 Pt 1):C339-C349.
70. Lowenstein CJ, Dinerman JL, Snyder SH. 1994. Nitric oxide: A physiologic messenger. Ann Int Med 120(3):227-237.
71. Luss H, Neumann J, Schmitz W, Schulz R, Heusch G. 2000. The stress-responsive MAP kinase p38 is activated by low-flow ischemia in the in situ porcine heart. J Mol Cell Cardiol 32:1787-1794.
72. Lyons C, Orloff B, Cunningham J. 1992. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 267:6370-6374.
73. Mackay K, Mochly-Rosen D. 2000. Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. J Mol Cell Cardiol 32:1585-1588.
74. Mann DL, Young JB. 1994. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105:897-904.
75. 2+]i and the toxic actions of the HIV coat protein GP120. Eur J Neurosci 11(4):1167-1178.
76. 2+ current. J Biol Chem 268:26286-26295.
77. Mitka M. 1998. 1998 Nobel prize winners are announced: Three discoverers of nitric oxide activity. JAMA 280(19):1648.
78. Murry CE, Jennings RB, Reimer KA. 1986. Preconditioning with ischemia, a delay of cell injury in ischemic myocardium. Circulation 74:1124-1136.
79. Nakano A, Baines CP, Kim SO, Pelech SL, Downey JM, Cohen MV, Critz SD. 2000a. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart. Evidence for involvement of p38 MAPK. Circ Res 86:144-151.
80. Nakano A, Cohen MV, Critz S, Downey JM. 2000b. SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol 95:466-471.
81. Obata T, Brown GE, Yaffe MB. 2000. MAP kinase pathways activated by stress: The p38 MAPK pathway. Crit Care Med 28(Suppl):N67-N77.
82. Oddis CV, Finkel MS. 1995. Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res Commun 213:(No. 3):1002-1009.
83. Oddis CV, Finkel MS. 1997. Cytokines and nitric oxide synthase inhibitor as mediators of adrenergic refractoriness in cardiac myocytes. Eur J Pharmacol 320:167-174.
84. Oddis CV, Simmons RL, Hattler BG, Finkel MS. 1995. cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes. Am J Physiol H38(6):2044-2050.
85. Ognibene FP, Rosenberg SA, Lotze MT, Skibber J, Parker MM, Shelhamer JH, Parillo JE. 1988. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94:750-754.
86. Packer M, Bristow MR, Cohn JN, et al., for the U.S. Carvedilol Heart Failure Study Group. 1996. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355.
87. Paine E, Palmantier R, Akiyama SK, Olden K, Roberts JD. 2000. Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway. J Biol Chem 275:11284-11290.
88. Parillo JE. 1993. Mechanisms of disease: Pathogenic mechanisms of septic shock. N Eng J Med 328:1471-1477.
89. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. 1985. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490.
90. ATP channels in ischaemic preconditioning. Cardiovasc Res 28:783-787.
91. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. 2001. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 15 37(4):1056-1061.
92. Ping P, Takano H, Zhang J, et al. 1999. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: A signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ Res 84:587-604.
93. Popik W, Hesselgesser JE, Pitha PM. 1998. Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway. J Virol 72:6406-6413.
94. Rapoport RM, Draznin MB, Murad F. 1983. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 306(5939):174-176.
95. Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE. 1989. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest 95:1072-1080.
96. Rockman HA, Koch WJ, Lefkowitz RJ. 2002. Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212.
97. Rozanski GJ, Witt RC. 1994. IL-1 inhibits beta-adrenergic control of cardiac calcium current: Role of L-arginine/nitric oxide pathway. Am J Phys 267(5 Pt 2):H1753-H1758.
98. Sadoshima J, Izumo S. 1993. Signal transduction pathways of angiotension II-induced c-fos gene expression in cardiac myocytes in vitro. Circ Res 73:424-438.
99. Shinke T, Takaoka H, Takeuchi M, Hata K, Kawai H, Okubo H, Kijima Y, Murata T, Yokoyama M. 2000. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to β-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. Circulation 101:1925-1930.
100. Smith LW, McDonough KH. 1988. Inotropic sensitivity to β-adrenergic stimulation in early sepsis. Am. J Physiol 255(Heart Circ Physiol 24):H699-H703.
101. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. 1993. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 106:1008-1016.
102. Sugden PH, Clerk A. 1998. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83:345-352.
103. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. 1979. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 2:1374-1376.
104. Sweetnam PM, Saab OH, Wroblewski JT, Price CH, Karbon EW, Ferkany JW. 1993. The envelope glycoprotein of HIV-1 alters NMDA receptor function. Eur J Neurosci 5(3):276-283.
105. Takano H, Tang XL, Qiu Y. 1998. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res 83:73-84.
106. Tatsumi T, Matoba S, Kawahara A, Keira N, Shiraishi J, Akashi K, Kobara M, Tanaka T, Katamura M, Nakagawa C, Ohta B, Shirayama T, Takeda K, Asayama J, Fliss H, Nakagawa M. 2000. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 35:1338-1346.
107. Vallance P, Moncada S. 1993. Role of endogenous nitric oxide in septic shock. New Horiz 1(1):77-86.
108. Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont E. 1992. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Chest 101:810-815.
109. Ward HE, Johnson EA, Salm AK, Birkle DL. 2000. Effects of prenatal stress on defensive withdrawal behavior and corticotropin releasing factor systems in rat brain. Physiol Behav 70(3-4):359-366.
110. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A, Troso T, Nathan C. 1992. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256:225-228.
111. Xu L, Eu JP, Meissner G, Stamler JS. 1998. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-s-nitrosylation. Science 27 9:234-236.
112. Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, Ohlstein EH. 2000. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86:692-699.
113. Zaragoza C, Ocampo C, Saura M, Leppo M, Wei XQ, Quick R, Moncada S, Liew FY, Lowenstein CJ. 1998. The role of inducible nitric oxide synthase in the host response to coxsackievirus myocarditis. Proc Natl Acad Sci USA 95(5):2469-2474.
114. ATP channels. Am J Physiol 280:H1278-H1285.
115. i or Gβγ in adult mouse cardiomyocytes. J Biol Chem 275:40635-40640.